Drug major Cipla today said it has received Establishment Inspection Report from the US health regulator for its Indore plant after completion of the inspection there.
The company has "received Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its Indore facility indicating formal closure of the USFDA inspection conducted in July/August, 2015," Cipla said in a filing to BSE.
EIR is given after the successful completion of the inspection by the USFDA.
Disclaimer: No Business Standard Journalist was involved in creation of this content
